0004340892190COINV8.

CSAII
Cyclosporine II Therapeutic drug monitoring
Order information
Analyzer(s) on which cobasc pack(s) can be used
COBASINTEGRA 400 plus
04340892 190 Cyclosporine II (100 tests) System-ID 0768227
COBAS INTEGRA 800
Cyclosporine Calibrators
System-ID 0766305
20766305 122 0 ng/mL (1 2.5 mL)
50, 100, 200, 350, 500 ng/mL (5 2.0 mL)
Cyclosporine Calibrator
20766399 122 System-ID 0766399
0 ng/mL (3 2.5 mL)
COBAS INTEGRA Cyclosporine Sample
20766364 122 System-ID 0766364
Pretreatment Reagent (4 40 mL)

English containing cyclosporine is then assayed using the COBASINTEGRA

CyclosporineII assay.
System information
Test CSAII, test ID 0007 Reagents - working solutions
Intended use R1 Antibody reagent
In vitro diagnostic test for the quantitative determination of cyclosporineA in Anti-cyclosporine monoclonal antibodies (mouse), nicotinamide
human whole blood as an aid in the management of cyclosporine therapy in adenine dinucleotide, glucose6phosphate, sodium chloride,
transplant patients. bulking agent, surfactant, and preservatives including 0.1%
Summary sodium azide and 0.005% streptomycin sulfate.
Cyclosporine is a cyclic undecapeptide of fungal origin and a potent SR Enzyme reagent
immunosuppressive agent. Since its introduction in 1983, cyclosporine has
substantially improved patient and graft survival in patients receiving heart, Cyclosporine labeled with bacterial (Leuconostoc mesenteroides)
kidney, liver, pancreas, or lung transplants. Many studies have documented glucose6phosphate dehydrogenase, TRIS buffer, bulking agents,
the effect of cyclosporine in combating organ rejection. Inadequate stabilizers, and preservatives including 0.1% sodium azide and
cyclosporine doses and levels may result in rejection of the transplanted 0.005% streptomycin sulfate.
organ. Toxic levels of cyclosporine are associated with many serious side
effects, including nephrotoxicity, hepatotoxicity, and a range of other R1 is in positionB and SR is in positionC.
complications. Physicians are particularly concerned with the nephrotoxic Precautions and warnings
effects of the drug in renal transplantation because of the difficulty in Pay attention to all precautions and warnings listed in
distinguishing between organ rejection and cyclosporine toxicity.1,2 Section1/Introduction of this Method Manual.
Monitoring parent drug cyclosporine concentrations in whole blood and For USA: For prescription use only.
interpreting these concentrations in conjunction with other laboratory data
and clinical considerations is the most effective means of ensuring Reagent handling
adequate immunosuppressant therapy for recipients of solid-organ Ready for use
transplants. Whole blood, rather than plasma, is the matrix of choice for the
measurement of cyclosporine since the drug is rapidly distributed into the Storage and stability
red blood cells. Cyclosporine concentrations should be measured using a
method that is specific for the parent drug because the contribution of the Shelf life at 28C See expiration date on
more than 30 cyclosporine metabolites to immunosuppression or toxicity cobasc pack label
remains uncertain. COBASINTEGRA400 plus system
The methods historically used to monitor cyclosporine concentrations in
blood include high performance liquid chromatography (HPLC), On-board in use at 1015C 4weeks
radioimmunoassay (RIA), and fluorescence polarization immunoassays COBASINTEGRA800 system
(FPIA).
On-board in use at 8C 4weeks
Test principle
Do not freeze reagents or expose them to temperatures above 27C. The
Enzyme Multiplied Immunoassay Technique (EMIT) cyclosporine calibrators are transported on dry ice and must be stored
The COBASINTEGRA CyclosporineII reagent is a homogeneous enzyme frozen. Prior to initial use, allow calibrators to thaw to room temperature for
immunoassay technique used for the analysis of cyclosporine in whole at least one hour.
blood. The assay contains mouse monoclonal antibodies with a high
specificity for cyclosporine. Specimen collection and preparation
The COBASINTEGRA CyclosporineII reagent is based on competition for For specimen collection and preparation only use suitable tubes or
cyclosporine antibody binding sites. collection containers.
Cyclosporine in the sample competes with cyclosporine in the Enzyme Only the specimens listed below were tested and found acceptable:
reagent that is labeled with the enzyme glucose6phosphate Whole blood
dehydrogenase (G6PDH). Active (unbound) enzyme converts oxidized The only acceptable anticoagulant is EDTA. Sample being tested should
nicotinamide adenine dinucleotide (NAD) in the Antibody reagent to NADH, not exceed 54% hematocrit.
resulting in a kinetic absorbance change that can be measured Pharmacokinetic factors influence the correct time of sample collection after
spectrophotometrically. Enzyme activity decreases upon binding to the the last drug dose. These factors include dosage, mode of administration,
antibody, allowing the cyclosporine concentration in the sample to be concomitant drug therapy, and biological variations affecting drug
measured in terms of enzyme activity. Endogenous serum G6PDH does not disposition. A trough sample is recommended for measurement of
interfere because the co-enzyme NAD functions only with the bacterial cyclosporine. Heparinized samples are not recommended because they
(Leuconostoc mesenteroides) enzyme employed in the assay. may form clots during storage. Use fresh samples. If samples are to be
Before testing with the COBASINTEGRA CyclosporineII assay, samples, tested within 8hours of collection, they may be stored at a room
calibrators, and controls must be pretreated with the COBASINTEGRA temperature of 1825C. They may be stored refrigerated at 28C for up
Cyclosporine Sample Pretreatment Reagent. The reagent lyses the cells, to one week. If longer storage is necessary, samples may be frozen at
extracts the cyclosporine, and precipitates blood proteins. The pretreated 20C. Cyclosporine has been shown to be stable in whole blood samples
samples are centrifuged, and an aliquot of the resulting supernatant for at least 3months when stored at 20C.3,4

2016-02, V 8.0 English 1/5 CSAII

0004340892190COINV8.0

CSAII
Cyclosporine II Therapeutic drug monitoring

Thaw and thoroughly mix frozen samples before testing. Repeated freeze- Reaction direction Increase
thaw cycles should be avoided. Insoluble materials that may form when
samples are frozen should be avoided when pipetting. Wavelength A/B 340/378 nm
ACTION REQUIRED Calc. first/last 74/170
Calibrators, controls, and/or samples must be pretreated with Postdilution factor No
COBASINTEGRA Cyclosporine Sample Pretreatment Reagent,
Cat.No.20766364122, system-ID0766364, before analysis. Follow the Unit ng/mL
steps described in the instructions for use of the COBASINTEGRA Cyclosporine is measured as long analysis test (duration approximately
Cyclosporine Sample Pretreatment Reagent to pretreat calibrators, 17minutes).
controls, and/or samples. The technical notes are an essential part of the
instructions and must be read thoroughly before completing each step. Pipetting parameters
Diluting high samples Diluent (H2O)
High samples (>500ng/mL) should be diluted with either the zero calibrator
or cyclosporine negative EDTA whole blood. R1 65 L 2 L
1. Invert or rock the high whole blood sample and the diluent (zero Sample 9 L 11 L
calibrator or cyclosporine negative EDTA whole blood) gently, but SR 26 L 14 L
thoroughly just before use.
Total volume 127 L
2. Combine one part high whole blood sample with two parts diluent.
3. Mix the diluted sample gently but thoroughly by repeated inversion. Calibration
4. Pretreat the diluted sample following the steps described in the Calibrator Cyclosporine Calibrators
instructions for use of the COBASINTEGRA Cyclosporine Sample
Pretreatment Reagent. Cyclosporine conc. 0, 50, 100, 200, 350, 500 ng/mL
(0, 41.6, 83.3, 167, 291, 416 nmol/L)
5. Assay the sample and multiply the result by 3 to obtain an estimate of
the cyclosporine concentration. Calibration mode Logit/log 4
Materials provided Calibration replicate Duplicate recommended
See Reagents working solutions section for reagents. Deviation low/high <10%at50ng/mL(41.6nmol/L)
Materials required (but not provided) Calibration interval Each cobasc pack and as required
following quality control procedures
For pretreatment of calibrators, controls, and/or samples use A calibration curve must be prepared using the Cyclosporine Calibrators.
COBASINTEGRA Cyclosporine Sample Pretreatment Reagent, Calibrators must be placed from the highest concentration(F) first, to the
Cat.No.20766364122, system-ID0766364. lowest(A) last, on the CAL/QC rack. This curve is retained in memory by
Assay the COBASINTEGRA systems and recalled for later use.
For optimum performance of the assay follow the directions given in this Traceability: The Cyclosporine Calibrators are prepared to contain known
document for the analyzer concerned. Refer to the appropriate operators quantities of cyclosporine in normal human serum and are traceable to USP
manual for analyzerspecific assay instructions. reference standards.
Application for whole blood Quality control
COBAS INTEGRA 400 plus test definition Quality Control BIO-RAD Lyphochek Whole Blood
Measuring mode Absorbance Immunosuppressant Controls
Abs. calculation mode Kinetic Control interval With each patient sample run
Reaction mode R1-S-SR Control sequence User defined
Reaction direction Increase Control after calibration Recommended
Wavelength A/B 340/378 nm The control intervals and limits should be adapted to each laboratorys
individual requirements. Values obtained should fall within the defined
Calc. first/last 50/102 limits. Each laboratory should establish corrective measures to be taken if
Postdilution factor No values fall outside the defined limits.
Follow the applicable government regulations and local guidelines for
Unit ng/mL quality control.
Cyclosporine is measured as long analysis test (duration approximately Calculation
17minutes).
COBASINTEGRAanalyzers automatically calculate the analyte
Pipetting parameters concentration of each sample. For more details, please refer to Data
Analysis in the Online Help (COBASINTEGRA400plus/800 analyzers).
Diluent (H2O) Conversion factor: ng/mL 0.833 = nmol/L
R1 65 L 2 L Limitations - interference
Sample 9 L 11 L See the Specific performance data section of this document for
SR 26 L 14 L information on substances tested with this assay. There is the possibility
that other substances and/or factors may interfere with the test and cause
Total volume 127 L erroneous results (e.g., technical or procedural errors).
The COBASINTEGRA CyclosporineII cobasc pack is for in vitro
COBAS INTEGRA 800 test definition diagnostic use in the measurement of cyclosporine in whole blood. This
Measuring mode Absorbance assay is not intended to be used for measuring cyclosporine in serum or
plasma. The effect of carry-over should be considered when evaluating a
Abs. calculation mode Kinetic low concentration sample that follows a sample with a cyclosporine
Reaction mode R1-S-SR concentration of 500ng/mL or higher. The amount of carry-over varies from
instrument to instrument. To minimize carry-over, properly maintain your

CSAII 2/5 2016-02, V 8.0 English

0004340892190COINV8.0

CSAII
Cyclosporine II Therapeutic drug monitoring

instrument and sample handling equipment, and carefully follow the assay Repeatability Mean SD CV
procedures. ng/mL (nmol/L) ng/mL (nmol/L) %
Criterion: Recovery within 10% of initial value at a cyclosporine Level 3 346 (288) 18 (15.0) 5.1
concentration of 85ng/mL (70.8nmol/L).
Icterus: No significant interference up to a bilirubin concentration of Intermediate precision Mean SD CV
855mol/L or 50mg/dL.
ng/mL (nmol/L) ng/mL (nmol/L) %
Hemolysis: No significant interference over a hematocrit range from
1554%. Level 1 90.8 (75.5) 9.0 (7.5) 9.9
Lipemia: No significant interference up to a triglycerides concentration of Level 2 185 (154) 13 (10.8) 6.9
1500mg/dL. Level 3 346 (288) 24 (20.0) 6.9
Uric acid: No significant interference up to an uric acid concentration of
20mg/dL.
Cholesterol: No significant interference up to a cholesterol concentration of The following results were obtained on the COBASINTEGRA800analyzer:
500mg/dL.
In very rare cases, gammopathy, in particular type IgM (Waldenstrms Repeatability Mean SD CV
macroglobulinemia), may cause unreliable results.5 ng/mL (nmol/L) ng/mL (nmol/L) %
For diagnostic purposes, the results should always be assessed in Level 1 92.8 (77.2) 6.9 (5.7) 7.5
conjunction with the patients medical history, clinical examination and other
findings. Level 2 191 (159) 10 (8.3) 5.2
ACTION REQUIRED Level 3 358 (298) 19 (15.8) 5.2
Special Wash Programming: The use of special wash steps is mandatory
when certain test combinations are run together on COBASINTEGRA Intermediate precision Mean SD CV
analyzers. Refer to the CLEAN Method Sheet for further instructions and for ng/mL (nmol/L) ng/mL (nmol/L) %
the latest version of the Extra wash cycle list.
Where required, special wash/carry-over evasion programming must Level 1 92.8 (77.2) 10 (8.3) 11.1
be implemented prior to reporting results with this test. Level 2 191 (159) 14 (11.7) 7.5
Limits and ranges Level 3 358 (298) 21 (17.5) 6.0
Measuring range
15500ng/mL (12.5416nmol/L)
Lower limits of measurement Method comparison
Lower detection limit of the test: The COBASINTEGRA Cyclosporine and COBASINTEGRA CyclosporineII
15ng/mL (12.5nmol/L) assays with COBASINTEGRA Cyclosporine Pretreatment Reagent were
compared to a commercially available EMIT assay using both a methanol
The lower detection limit represents the lowest measurable analyte level (MeOH) extraction method and a commercially available EMIT cyclosporine
that can be distinguished from the zero calibrator at a 95% confidence sample pretreatment reagent on the COBASMIRA analyzer.
level. It was determined using the zero calibrator. The result was obtained COBASINTEGRA Cyclosporine and COBASINTEGRA CyclosporineII
on all the COBASINTEGRA analyzers. assays showed equivalent performance compared to EMIT Cyclosporine
Expected values assay. The data shown below is representative of the comparisons.
No firm therapeutic range exists for cyclosporine in whole blood. The Samples used for method comparisons came from 277 whole blood
complexity of the clinical state, individual differences in sensitivity to samples collected from post-transplant patients. In some cases, more than
immunosuppressive and nephrotoxic effects of cyclosporine, one sample may have been drawn from the same patient at different post-
coadministration of other immunosuppressants, type of transplant, time transplant times. Samples were frozen at 20C and analyzed within a
post transplant, and a number of other factors contribute to different month of being drawn. Of these 277, 14samples from the MeOH
requirements for optimal blood levels of cyclosporine. Individual comparison, and 15samples from the new pretreatment comparison, were
cyclosporine values cannot be used as the sole indicator for making shown to contain cyclosporine concentrations of <40ng/mL (EMIT
changes in the treatment regimen. Each patient should be thoroughly sensitivity) or >500ng/mL (test limit), and were omitted from the statistical
evaluated clinically before treatment adjustments are made, and each analysis. The remaining sample population is comprised of three transplant
assay user must establish his or her ranges based on clinical experience. types, 24liver, 93heart, and 145kidney (for COBASINTEGRA700
analyzer Cyclosporine vs. EMIT with pretreatment reagent comparison) or
These ranges will vary according to the commercial in vitro diagnostic 146kidney (for COBASINTEGRA700 analyzer Cyclosporine vs. EMIT with
test used. Ranges must be established for each commercial test used. methanol extraction comparison).
Each laboratory should investigate the transferability of the expected values Statistical analysis using the Deming regression method is provided below.
to its own patient population and if necessary determine its own reference
ranges. EMIT
Specific performance data EMIT Sample
Representative performance data on the COBASINTEGRA analyzers are MeOH Pretreatment
given below. Results obtained in individual laboratories may differ. Reagent
Precision Number of samples 263 262
Precision was determined using Bio-Rad Lyphochek Whole Blood Controls Range of values min. 41 ng/mL 43 ng/mL
in accordance with the CLSI guidelines EP05A26 requirements with
repeatability (n=84) and intermediate precision (2aliquots per run, 2runs max. 489 ng/mL 485 ng/mL
per day, 21days). Slope 0.937 0.939
The following results were obtained on a COBASINTEGRA400 analyzer: 95 % confidence interval
Repeatability Mean SD CV lower limit 0.915 0.917
ng/mL (nmol/L) ng/mL (nmol/L) % upper limit 0.959 0.961
Level 1 90.8 (75.5) 6.1 (5.1) 6.7 Intercept (ng/mL) 12.9 13.3
Level 2 185 (154) 8 (6.7) 4.6 95 % confidence interval

2016-02, V 8.0 English 3/5 CSAII

0004340892190COINV8.0

CSAII
Cyclosporine II Therapeutic drug monitoring

lower limit 8.0 8.1 Level tested Cross-reactivity

upper limit 17.8 18.6 Drug ng/mL %
Correlation coefficient 0.968 0.963 (AM9) M1 667 13
The same data sets are shown below in Bland-Altman difference plots. (AM19) M8 500 3.2
(AM1) M17 500 ND
COBASINTEGRA700 analyzer Cyclosporine vs. EMIT with Methanol (AM4N) M21 500 5.1
Extraction
ND = Not Detectable
Level tested Cross-reactivity
Drug ng/mL %
Acetaminophen 200 ND
Albuterol 0.18 ND
Allopurinol 600 ND
Alprazolam 0.37 ND
Amphoteracin B 20 ND
Atenolol 40 ND
Azathiopoprine 10 ND
N = 263 Captopril 50 ND
Mean (Y-X) = -0.3 Carbamazepine 120 ND
SD (Y-X) = 23.0 Ceflacor 230 ND
2 SD = 46.0 Chloramphenicol 250 ND
Mean + 2 SD = 45.7 Cimetidine 100 ND
Mean - 2 SD = -46.4 Cyclophosphamide 250 ND
Digoxin 0.02 ND
COBASINTEGRA700 analyzer Cyclosporine vs. EMIT with
Pretreatment Reagent Dipyridamole 25 ND
Disopyramidine 30 ND
Erythromycin 200 ND
Furosemide 20 ND
Gancyclovir 400 ND
Gentamicin 120 ND
Heparin 800 U/L ND
Hydralazine 32 ND
Hydrochlorothiazide 40 ND
Isoniazid 70 ND
Isoproterenol hydrochloride 0.06 ND
N = 262
Lidocaine 600 ND
Mean (Y-X) = 0.4
Methylprednisolone 12 ND
SD (Y-X) = 24.3
Metoclopramide 4 ND
2 SD = 48.5
Mycophenolic acid 100 ND
Mean + 2 SD = 48.9
Naproxen 1000 1.5
Mean - 2 SD = -48.1
Phenobarbital 150 ND
Analytical specificity3
The following metabolites, cross-reactive substances, and structurally Phenytoin 100 11.8
related or potentially co-administered compounds were evaluated on the Piperacillin 8 ND
COBASINTEGRA systems in a normal human EDTA whole-blood pool
spiked with cyclosporine at 200ng/mL (166.5nmol/L). Each substance was Prazosin 3 ND
tested at 10times the highest concentration for its therapeutic or normal Prednisolone 12 ND
range, as per the protocol described by NCCLS.7 The imprecision of the
assay was taken into account when determining cross-reactivity. Cross- Prednisone 12 ND
reactivity was designated as not detectable (ND) if the obtained value was Promethazine 10 ND
less than the sensitivity of the assay.
Salicylic acid 500 ND
100(analytical result-analyte concentration)
Cross-reactivity (%) = Sulfamethoxazole 400 ND
concentration of interferent
Theophylline 250 ND

CSAII 4/5 2016-02, V 8.0 English

0004340892190COINV8.0

CSAII
Cyclosporine II Therapeutic drug monitoring

COBAS, COBASC, COBASINTEGRA and COBASMIRA are trademarks of Roche.

Level tested Cross-reactivity
All other product names and trademarks are the property of their respective owners.
Drug ng/mL %
Additions, deletions or changes are indicated by a change bar in the margin.
Triamterene 2.8 ND 2015, Roche Diagnostics

Trimethoprim 20 ND
Vancomycin 630 ND
ND = Not Detectable Roche Diagnostics GmbH, SandhoferStrasse116, D-68305 Mannheim
www.roche.com
Linearity
Distribution in USA by:
To assess the linearity of the assay, a 7level dilution series was prepared Roche Diagnostics, Indianapolis, IN
using a whole blood sample from a patient taking cyclosporine diluted with US Customer Technical Support 1-800-428-2336
negative human whole blood. Results were evaluated by Passing/Bablok
regression.8
y = 0.998x + 1.07
r = 1.0
Slope 95 % CI (0.971, 1.02)
Intercept 95 % CI (-0.610, 11.1)
Lower limit of the range = 28.1
Any modification of the instrument as set forth in this labeling requires
validation by the laboratory.
References
1 McMillan MA. Clinical pharmacokinetics of cyclosporine. Pharmac Ther
1989;42:135-156.
2 Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-1738.
3 Schran HF, Rosano TG, Hassell AE, et al. Determination of
cyclosporine concentrations with monoclonal antibodies. Clin Chem
1987;33:2225-2229.
4 Wong PY, Mee AV, Glenn J, et al. Quality assessment of cyclosporine
monitoring Canadian validations. Transplant Proc 1990;22:1216-1217.
5 Bakker AJ, Mcke M. Gammopathy interference in clinical chemistry
assays: mechanisms, detection and prevention.
ClinChemLabMed2007;45(9):1240-1243.
6 Clinical and Laboratory Standards Institute. Evaluation of Precision of
Quantitative Measurement Methods:Approved Guideline, EP05A2
2004.
7 National Committee for Clinical Laboratory Standards. Interference
Testing in Clinical Chemistry; Proposed Guideline. Villanova, PA.:
NCCLS; 1986;6(13). NCCLS Publication EP7-P.
8 Bablok W, Passing H, Bender R, et al. A general regression procedure
for method transformation. Application of linear regression procedures
for method comparison studies in clinical chemistry, Part III. J Clin
Chem Clin Biochem 1988 Nov;26(11):783-790.
A point (period/stop) is always used in this Method Sheet as the decimal
separator to mark the border between the integral and the fractional parts of
a decimal numeral. Separators for thousands are not used.
Symbols
Roche Diagnostics uses the following symbols and signs in addition to
those listed in the ISO 152231 standard.
Contents of kit
Volume after reconstitution or mixing
GTIN Global Trade Item Number

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications
stated in the labeling when used in accordance with such labeling and will
be free from defects in material and workmanship until the expiration date
printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY
OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED
WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR
PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE
FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL
DAMAGES.

2016-02, V 8.0 English 5/5 CSAII